{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-24-000006","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2024-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.962141+00:00","generated_at":"2026-06-05T21:51:57.207588+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emergent BioSolutions appoints Joseph C. Papa as President and CEO, replacing interim CEO Haywood Miller","bullets":["Joseph C. Papa appointed President and CEO effective Feb 21, 2024; succeeds interim CEO Haywood Miller.","Papa brings over 35 years pharma experience, most recently CEO of Bausch + Lomb (NYSE: BLCO).","Compensation: $1M base salary, 130% bonus target, $1M sign-on bonus, 1.5M stock options, $8M performance incentive tied to share price.","Also appointed Class II director with term through 2026 annual meeting.","Press release emphasizes focus on strengthening balance sheet, returning to growth, and paying down debt."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-24-000006","json":"https://secwatch.observer/filing/0001367644-24-000006.json","markdown":"https://secwatch.observer/filing/0001367644-24-000006.md","text":"https://secwatch.observer/filing/0001367644-24-000006.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/ebs-20240220.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T21:51:57.207588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2c170e6234","claim":"Joseph C. Papa was appointed as President and CEO at Emergent BioSolutions Inc..","evidence_excerpt":"appointed Joseph C. Papa as President and CEO of the Company, effective February 21, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and CEO"}],"fact_type":"executive_change"},{"claim_id":"4e8be3a2eb","claim":"Joseph C. Papa was appointed as Class II director at Emergent BioSolutions Inc..","evidence_excerpt":"Mr. Papa has been appointed as Class II director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"c72b825702","claim":"Haywood Miller departed as Interim CEO at Emergent BioSolutions Inc..","evidence_excerpt":"Haywood Miller, who will step down from his role as interim CEO of the Company, effective February 21, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1367644/000136764424000006/0001367644-24-000006-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"stepped down"},{"label":"Role","value":"Interim CEO"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}